Compare Ginkgo Bioworks Holdings Inc (DNA) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs New York Times Co — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.42 (market cap $505.73M), while New York Times Co trades at $64.25 (market cap $10.28B). The key difference: New York Times Co is far larger — about 20.3× Ginkgo Bioworks Holdings Inc's market cap, and New York Times Co pays a 1.44% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | NYT | |
|---|---|---|
Market Cap | $505.73M | $10.28B |
Sector | Health | Media |
52-Week High | $16.14 | $85.86 |
52-Week Low | $5.48 | $54.66 |
Enterprise Value | $607.68M | $9.67B |
Dividend Yield | — | 1.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
The New York Times (NYT) stock trades at $64.21, down 0.91% on the day, with a bearish technical signal despite recent earnings beats. Revenue growth remains steady, reaching $2.82 billion in 2025, with net income margins improving to 12.17%. The company faces headwinds from slowing digital subscriber growth, as highlighted in recent quarterly reports, but maintains strong profitability and cash flow generation.
Outlook is mixed; valuation appears full with a P/E of 26.55, yet analyst consensus targets $77.50 suggest upside. Key risks include subscriber growth moderation and competitive pressures. The stock offers a dividend yield with the next payment scheduled for July 23, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
